search
Back to results

Efficacy Evaluation of Hydrolyzed Collagen Peptide on Knees, Hips, and Ankle Pain in Osteoarthritis

Primary Purpose

Pain, Joint

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Hydrolyzed Collagen Peptide
Sponsored by
Sel Sanayi Urunleri Ticaret ve Pazarlama A.S.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Pain, Joint

Eligibility Criteria

45 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male and female individuals with osteoarthritis on knee who are aged between 45-60 years old,
  2. Who are not drug-naïve to osteoarthritis and related conditions,
  3. Volunteers who have ability to communicate adequately with the investigator and in agreement to comply with the study requirements,
  4. Volunteers who have normal blood pressure and heart rate measured under stabilised conditions at the screening visit after at least 5 minutes of rest under supine position: SBP within 100 to 140 mmHg, DBP within 60 to 90 mmHg and HR within 50 to 100 bpm at least after 5 minutes of rest,
  5. Volunteers who have understanding of the study and agreement to give a written informed consent.

Exclusion Criteria:

  1. Who have atopic constitution or asthma and/or known allergy for bovine derived collagen products and/or other any of the excipients of the product.
  2. Who have hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption.
  3. Who have an active rheumatoid arthritis or any other inflammatory arthritic condition that researchers consider non appropriate.
  4. Who have Diabetes Mellitus.
  5. Who have the use of oral retinoids or oral steroids in the 6 months prior to initiation of the study.
  6. Who have current participation in another clinical study, or participation in a relevant study within 3 months.
  7. Who have any history or presence of serious or life-threatening conditions of cardiovascular, neurological, haematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological, metabolism or psychiatric disease, any type of porphiria.
  8. Who have the presence or history of malabsorption or any gastrointestinal surgery except appendectomy or except herniotomy.
  9. Who are planned to go or already went under a joint-related reconstructive surgery,
  10. For female volunteers, who had undergone, or planned to undergo, pregnancy or breastfeeding.
  11. Who have current or regular intake of NSAIDS, contraceptives, hormones, obesity drugs, absorption inhibitors or antidepressants
  12. Who are suspected to have a high probability of non-compliance to the study procedure and/or completion of the study according to the investigator's judgment.
  13. Who have history of drug abuse.
  14. Who have relationship to the investigator.
  15. Who are not suitable to any of inclusion criteria.
  16. Who have history of difficulty of swallowing.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Hydrolized Collagen Peptide

    Placebo

    Arm Description

    This arm will be allocated randomly and receive 10 g hydrolized collagen peptide (Investigational Product) daily throughout the study.

    This arm will be allocated randomly and receive placebo daily throughout the study.

    Outcomes

    Primary Outcome Measures

    Amelioration on Knee Pain
    Amelioration on knee joint pain, stiffness and physical function according to WOMAC (The Western Ontario and McMaster Universities Osteoarthritis Index) score.

    Secondary Outcome Measures

    Amelioration on Hip Pain
    Amelioration on pain, stiffness and physical function of joints of hip according to WOMAC score.
    Amelioration on Ankle Pain
    Amelioration on pain and physical function of ankles according to AOFASAHFS (American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Scale) scale.

    Full Information

    First Posted
    May 6, 2022
    Last Updated
    May 6, 2022
    Sponsor
    Sel Sanayi Urunleri Ticaret ve Pazarlama A.S.
    Collaborators
    Alpan Farma Ar-Ge Biyoteknolojileri Ltd.Sti.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05369780
    Brief Title
    Efficacy Evaluation of Hydrolyzed Collagen Peptide on Knees, Hips, and Ankle Pain in Osteoarthritis
    Official Title
    A Multiple-Dose, Randomized, Double-Blinded, Placebo Controlled Trial To Evaluate The Efficacy Of Hydrolyzed Collagen Peptide On Knees, Hips, and Ankle Pains In Adults With Osteoarthritis
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    May 15, 2022 (Anticipated)
    Primary Completion Date
    May 15, 2023 (Anticipated)
    Study Completion Date
    May 15, 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Sel Sanayi Urunleri Ticaret ve Pazarlama A.S.
    Collaborators
    Alpan Farma Ar-Ge Biyoteknolojileri Ltd.Sti.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The aim of this study is to evaluate the effectiveness of Hydrolyzed collagen peptides on joint pain, stiffness and physical function in adults with osteoarthritis who have complaints on knee joints together with hip and ankles. The assessment of improvements on volunteers' quality of life, and safety and tolerability of the product is the other objective of this placebo-controlled, randomized study.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pain, Joint

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    160 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Hydrolized Collagen Peptide
    Arm Type
    Experimental
    Arm Description
    This arm will be allocated randomly and receive 10 g hydrolized collagen peptide (Investigational Product) daily throughout the study.
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    This arm will be allocated randomly and receive placebo daily throughout the study.
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Hydrolyzed Collagen Peptide
    Other Intervention Name(s)
    Collagen
    Intervention Description
    Dietary Hydrolized Collagen Peptide sourced from bovine
    Primary Outcome Measure Information:
    Title
    Amelioration on Knee Pain
    Description
    Amelioration on knee joint pain, stiffness and physical function according to WOMAC (The Western Ontario and McMaster Universities Osteoarthritis Index) score.
    Time Frame
    2 months
    Secondary Outcome Measure Information:
    Title
    Amelioration on Hip Pain
    Description
    Amelioration on pain, stiffness and physical function of joints of hip according to WOMAC score.
    Time Frame
    2 months
    Title
    Amelioration on Ankle Pain
    Description
    Amelioration on pain and physical function of ankles according to AOFASAHFS (American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Scale) scale.
    Time Frame
    2 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    45 Years
    Maximum Age & Unit of Time
    60 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male and female individuals with osteoarthritis on knee who are aged between 45-60 years old, Who are not drug-naïve to osteoarthritis and related conditions, Volunteers who have ability to communicate adequately with the investigator and in agreement to comply with the study requirements, Volunteers who have normal blood pressure and heart rate measured under stabilised conditions at the screening visit after at least 5 minutes of rest under supine position: SBP within 100 to 140 mmHg, DBP within 60 to 90 mmHg and HR within 50 to 100 bpm at least after 5 minutes of rest, Volunteers who have understanding of the study and agreement to give a written informed consent. Exclusion Criteria: Who have atopic constitution or asthma and/or known allergy for bovine derived collagen products and/or other any of the excipients of the product. Who have hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption. Who have an active rheumatoid arthritis or any other inflammatory arthritic condition that researchers consider non appropriate. Who have Diabetes Mellitus. Who have the use of oral retinoids or oral steroids in the 6 months prior to initiation of the study. Who have current participation in another clinical study, or participation in a relevant study within 3 months. Who have any history or presence of serious or life-threatening conditions of cardiovascular, neurological, haematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological, metabolism or psychiatric disease, any type of porphiria. Who have the presence or history of malabsorption or any gastrointestinal surgery except appendectomy or except herniotomy. Who are planned to go or already went under a joint-related reconstructive surgery, For female volunteers, who had undergone, or planned to undergo, pregnancy or breastfeeding. Who have current or regular intake of NSAIDS, contraceptives, hormones, obesity drugs, absorption inhibitors or antidepressants Who are suspected to have a high probability of non-compliance to the study procedure and/or completion of the study according to the investigator's judgment. Who have history of drug abuse. Who have relationship to the investigator. Who are not suitable to any of inclusion criteria. Who have history of difficulty of swallowing.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Aydın Erenmemişoğlu, Prof. Dr.
    Phone
    +90 532 551 0082
    Email
    aydin@alpanfarma.com

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Efficacy Evaluation of Hydrolyzed Collagen Peptide on Knees, Hips, and Ankle Pain in Osteoarthritis

    We'll reach out to this number within 24 hrs